# Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

> **NCT03201458** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 86 (actual)

## Conditions studied

- Gallbladder Carcinoma
- Metastatic Cholangiocarcinoma
- Stage III Intrahepatic Cholangiocarcinoma AJCC v8
- Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
- Unresectable Cholangiocarcinoma

## Interventions

- **DRUG:** Atezolizumab
- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Cobimetinib
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT03201458
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-08
- **Primary completion:** 2020-08-07
- **Final completion:** 2024-02-19
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2024-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03201458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03201458, "Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03201458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*